Next, we exploited the cooperation between loss of function of TET2 and KIT D816V in the HMC-1.2 cell line to validate possible combinatorial approaches to treatment for ASM and MCL [8], [33]. This evidence concerns the gene TET2 and mantle cell lymphoma.